
    
      Up to 58 weeks, including a Screening Period consisting of a Screening phase of up to 2
      weeks, a 2-week single-blind placebo Run-in phase, a 52-week double-blind Treatment Period,
      and a 2-week post-treatment Follow-up period to collect safety information.
    
  